Currently, MAPS seeks $9 million for European Medicines Agency (EMA) trials to supplement the data gathered for the FDA, with $897,735 already raised and roughly $8.1 million still to go. We have completed key negotiations with EMA, and we will have a more precise estimate of timetables and costs for Phase 3 EMA trials in mid-2019 after completion of our negotiations with each country in the EMA in which we will have a Phase 3 site, and with each site.
In February 2019, MAPS raised $1.67 million in new donations and pledges from 790 supporters. Of that amount, $1.62 million was for general support, and $51,123 for MDMA/PTSD Phase 3.
We extend a special thanks to those who so generously supported MAPS last month:
- TIDES Foundation ($1.5 million)
- Robert Anthony Granieri ($50,000)
- David and Lisa Seligman ($15,000)
- Anonymous ($10,000)
- Jeffrey Zucker ($5,000)
- Anonymous ($5,000)
- John Heilemann ($2,000)
- Iiro Jalava ($1,000)
- Patrick Smith ($1,000)
- Ibrahim AlHusseini ($1,000)
MDMA/PTSD Phase 3 Research:
- Anonymous ($50,000)
MAPS fiscally sponsors like-minded organizations and projects. This list includes donors who have contributed to organizations we fiscally sponsor.
- Anonymous ($300,000 – Mission Within)
- William Nathan ($25,000 – Prescription X)
- CIIS ($2,000 – Psychedelic Integration 2019)
- Brad Coy ($1,500 – Psychedelic Integration 2019)
- Matt Myers ($1,250 – Mission Within)
MAPS relies on the generosity of individual donors to achieve its mission. Psychedelic science is again being conducted under federal guidelines, but no funding for psychedelic psychotherapy research is yet available from governments or major foundations.
Help us reach our goal to make MDMA a medicine by 2021 by establishing a monthly gift of $10 or more. maps.org/donate